On Nov 01, major Wall Street analysts update their ratings for $IQVIA Holdings (IQV.US)$, with price targets ranging from $235 to $270.
BofA Securities analyst Michael Ryskin maintains with a buy rating, and adjusts the target price from $260 to $255.
Barclays analyst Luke Sergott maintains with a buy rating, and adjusts the target price from $260 to $255.
Evercore analyst Elizabeth Anderson CFA maintains with a buy rating, and adjusts the target price from $265 to $235.
TD Cowen analyst Charles Rhyee maintains with a buy rating, and maintains the target price at $255.
Mizuho Securities analyst Ann Hynes maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $IQVIA Holdings (IQV.US)$'s main analysts recently are as follows:
The market's stability was noted by the company, while issues with bookings were attributed to delays and drug failures rather than significant effects from pipeline rationalization.
The company has been navigating a difficult industry operating landscape. Commentary from the company indicates that the pharmaceutical portfolio adjustments related to the IRA may be concluding, and the company seems poised to benefit from the pharmaceutical industry's trend towards vendor consolidation.
Iqvia's recent financial performance surpassed consensus expectations in total revenue, adjusted EBITDA, and adjusted EPS. However, the company has revised its 2024 guidance downwards for all metrics. This revision is attributed to the challenges posed by the Inflation Reduction Act and broader economic factors. Additionally, the guidance for R&DS has been impacted by the delay and cancellation of two significant trials.
Concerns are being raised about near-term CRO marketplace dynamics. With a significant portion of the company experiencing a slow or weakening trend, there are questions about whether the improving segment will do more than just maintain equilibrium.
Here are the latest investment ratings and price targets for $IQVIA Holdings (IQV.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月1日，多家華爾街大行更新了$艾昆緯 (IQV.US)$的評級，目標價介於235美元至270美元。
美銀證券分析師Michael Ryskin維持買入評級，並將目標價從260美元下調至255美元。
巴克萊銀行分析師Luke Sergott維持買入評級，並將目標價從260美元下調至255美元。
Evercore分析師Elizabeth Anderson CFA維持買入評級，並將目標價從265美元下調至235美元。
TD Cowen分析師Charles Rhyee維持買入評級，維持目標價255美元。
瑞穗證券分析師Ann Hynes維持買入評級。
此外，綜合報道，$艾昆緯 (IQV.US)$近期主要分析師觀點如下：
公司指出市場的穩定性，而訂購問題被歸因於延遲和藥品失敗，而不是來自管道合理化的重大影響。
公司一直在應對行業經營環境的困難。該公司的評論表明，與IRA相關的藥品組合調整可能即將結束，並且公司似乎將從藥品行業向供應商整合趨勢中獲益。
Iqvia最近的財務表現超過了總營收、調整後的EBITDA和調整後的每股收益的共識預期。然而，該公司已將2024年的所有指標指引下調。這一修訂歸因於通貨膨脹減少法案和更廣泛的經濟因素帶來的挑戰。此外，研發支出的指引受到了兩項重大試驗的延期和取消的影響。
近期對CRO市場動態產生了擔憂。公司的相當一部分經歷了緩慢或趨弱的趨勢，人們開始質疑改善的部分是否會僅僅保持平衡以上。
以下爲今日8位分析師對$艾昆緯 (IQV.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
